|本期目录/Table of Contents|

[1]孙桂江 综 述,姜埃利 审 校.血流动力学相关心肾综合征的治疗进展[J].天津医科大学学报,2018,24(06):571-574.
点击复制

血流动力学相关心肾综合征的治疗进展(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24卷
期数:
2018年06期
页码:
571-574
栏目:
综述
出版日期:
2018-11-20

文章信息/Info

Title:
-
作者:
孙桂江 综 述 姜埃利 审 校
Author(s):
-
关键词:
-
Keywords:
-
分类号:
-
DOI:
-
文献标志码:
-
摘要:
-
Abstract:
-

参考文献/References:


[1] Thervet ?魪. Pathophysiology of cardiorenal syndrome[J]. Rev Prat,2016,66(6):611
[2] Virzì G M,Clementi A,Ronco C. Cellular apoptosis in the cardiorenal axis[J]. Heart Fail Rev,2016,27(2):177
[3] Verbrugge F H,Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure[J]. Cardiorenal Med, 2014,4:176
[4] Moulin B. Cardiorenal syndromes: Definition and classification[J]. Rev Prat,2016,66(6):608
[5] Palazzuoli A,Ruocco G,Pellegrini M, et al. Patients with cardiorenal syndrome revealed increased neurohormonal activity,tubular and myocardial damage compared to heart failure patients with preserved renal function[J]. Cardiorenal Med,2014,4:257
[6] De Franceschi L,Iolascon A,Taher A, et al. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment[J]. Eur J Intern Med,2017,42(7):16
[7] Ponikowski P,VanVeldhuisen D J, Comin-Colet J A, et al.Beneficial effects of long-term intravenous Iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and Iron deficiency[J]. Eur Heart J,2015,36(11):657
[8] Heine G H. Mineral metabolism in heart disease[J]. Curr Opin Nephrol Hypertens,2015,24(4):310
[9] Members W C,Yancy C W,Jessup M, et al.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation,2013, 128(16):e240
[10] Xing F, Hu X, Jiang J, et al. A meta-analysis of low-dose dopamine in heart failure[J]. Int J Cardiol,2016,1(11):1003
[11] Chen H H, Anstrom K J, Givertz M M, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure withrenal dysfunction: the ROSE acute heart failure randomized trial[J]. JAMA, 2013, 310:2533
[12] Husebye T,Eritsland J,Muller C,et al. Levosimendan in acute heart failure following primary percutaneouscoronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: arandomized, placebo-controlled study[J]. Eur J Heart Fail, 2013,15:565
[13] Koster G,Wetterslev J,Gluud C,et al. Effects of levosimendan for low cardiac output syndrome in critically illpatients: systematic review with meta-analysis and trial sequential analysis[J]. Intensive Care Med,2015,41:203
[14] Zangrillo A,Alvaro G,Belletti A,et al. Effect of levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: A substudy of a multicenter randomized trial[J]. J Cardiothorac Vasc Anesth, 2018,2
[15] Gencer E, Dogan V, ?魻ztürk M T, et al. Comparison of the effects of levosimendan dobutamine and vasodilator therapy on ongoing myocardial injury in acute decompensated heart failure[J]. J Cardiovasc Pharmacol Ther, 2016,7(7):1
[16] Balint I, Vuak J, Ba?觢i-Markovi N, et al. Pathophysiology of the cardiorenal syndrome[J]. Acta Med Croatica, 2016,70(12):325
[17] Tuttolomondo A,Parrinello G,Pinto A. Diuretic treatment in heart failure[J]. N Engl J Med,2018,378(7):683
[18] Palazzuoli A, Pellegrini M, Ruocco G, et al. Continuous versus bolus intermittent loop diuretic infusion inacutely decompensated heart failure: a prospective randomized trial[J]. Crit Care, 2014,18:R134
[19] Bart B A,Goldsmith S R,Lee K L, et al.Ultrafiltration in decompensated heart failure with cardiorenal syndrome[J]. N Engl J Med,2012,367(24):2296
[20] Marenzi G,Muratori M,Cosentino E R,et al. Continuous ultrafiltration for congestive heart failure: the CUORE trial[J]. J Card Fail,2014,20(1):9
[21] Mentz R J, Stevens S R, DeVore A D, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure[J]. JACC Heart Fail, 2015,3:97
[22] Schneider A G,Bellomo R,Bagshaw S M, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis[J]. Intensive Care Med,2013,39(6):987
[23] Küllmar M, Zarbock A. Renal Replacement therapy in acute kidney injury-indication and implementation[J]. Anasthesiol Intensivmed Notfallmed Schmerzther, 2018,53(2):150
[24] Wald R, Shariff S Z, Adhikari N K, et al. The association between renal replacement therapy modality and longterm outcomes among critically ill adults with acute kidney injury: a retrospective cohort study [J]. Crit Care Med, 2014,42:868
[25] Schwenger V,Weigand M A, Hoffmann O,et al. Sustained low efficiency dialysis using a single-pass batchsystem in acute kidney injury-a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts[J]. Crit Care,2012, 16:R140
[26] Yamazoe M, Mizuno A,Kohsaka S,et al. Incidence of hospital-acquired hyponatremia by the dose and type of diuretics among patients with acute heart failure and its association with long-term outcomes[J]. J Cardiol,2018,5
[27] Ezekowitz J A, Podder M, Hernandez A F,et al. Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF)[J]. BMJ Open,2016,6(3):229
[28] Bronicki R A, Domico M, Checchia P A, et al.The use of nesiritide in patients with critical cardiac disease[J]. Cardiol Young,2017, 27(8):1577
[29] Voors A A,Dorhout B,van der Meer P. T he potential role of valsartan +AHU377 (LCZ696) in the treatment ofheartfailure[J]. Expert Opin Inves Drugs,2013,22:1041
[30] Mcmurray J J,PackerM,Desai A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014, 371(11):993

相似文献/References:

备注/Memo

备注/Memo:
作者简介 孙桂江(1981-),男,主治医师,硕士,研究方向:肾脏病及血液净化治疗;通信作者:姜埃利,E-mail:carlos_j@126.com。
更新日期/Last Update: 2018-11-30